235 Preclinical evaluation and anti-tumor activity of AZD6422, a CLDN18.2 targeting armored CAR-T for gastric, esophageal and pancreatic cancers

• Mark Cobbold,
• Nicolas Giraldo,
• Gordon Moody,
• Allison Barrett,
• Jean-Martin Lapointe,
• Shannon Breen,
• Rosa Carrasco,
• Zachary Britton,
• Benjamin Clark,
• Maria AS Broggi,
• Bala NN Rao Attili,
• Amy Hatke,
• Christina Grigoriadou,
• Melissa Damschroder,
• Emily Bosco

Affiliations

Mark Cobbold

Aff293 grid.32224.350000000403869924Massachusetts General Hospital Cancer Center Boston MA USA

Nicolas Giraldo

Aff1 0000 0001 2171 9311grid.21107.35Johns Hopkins University School of Medicine Baltimore MD USA

Gordon Moody

AstrZeneca, gaithersburg, MD, USA

Allison Barrett

1AstraZeneca, Gaithersburg, MD, USA

Jean-Martin Lapointe

5 Clinical Pharmacology & Safety Sciences, AstraZeneca PLC, Cambridge, Cambridgeshire, UK

Shannon Breen

1AstraZeneca, Gaithersburg, MD, USA

Rosa Carrasco

AstraZeneca, Gaithersburg, MD, USA

Zachary Britton

1AstraZeneca, Gaithersburg, MD, USA

Benjamin Clark

1AstraZeneca, Gaithersburg, MD, USA

Maria AS Broggi

1AstraZeneca, Gaithersburg, MD, USA

Bala NN Rao Attili

2AstraZeneca, Cambridge, UK

Amy Hatke

1AstraZeneca, Gaithersburg, MD, USA

Christina Grigoriadou

1AstraZeneca, Gaithersburg, MD, USA

Melissa Damschroder

1AstraZeneca, Gaithersburg, MD, USA

Emily Bosco

1AstraZeneca, Gaithersburg, MD, USA